Parallel Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Parallel Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50	Closed	-$72	–	3501
2023 Q3	$72	Hold	50	–	–	﹤0.01%	3297
2023 Q2	$125	Hold	50	–	–	﹤0.01%	3271
2023 Q1	$134	Hold	50	–	–	﹤0.01%	3313
2022 Q4	$272	Hold	50	–	–	﹤0.01%	3140
2022 Q3	$1K	Buy	+50	New	+$571	﹤0.01%	3063

Other funds holding GTHX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Parallel Advisors's GTHX Position: Q4 2023 in Review

Parallel Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2023, closing a stake of 50 shares — an estimated $72 sold.

Parallel Advisors first reported a position in GTHX in Q3 2022 and held it in 5 quarters. The position peaked at $1K in Q3 2022. 87 funds tracked by Wall St. Rank hold GTHX as of Q4 2023.

Parallel Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Parallel Advisors sold 50 G1 Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $72.
Parallel Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Parallel Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
87 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Parallel Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.